Launch of Adaptive’s COVID-19 T cell test fills gaps between viral and serological assays

Adaptive’s T-Detect is bringing T cell-based COVID-19 tests out of the research arena and into clinical use, with the primary goal of identifying individuals, including Long COVID patients, who cleared the virus without forming antibodies. 

Developed through a partnership between  Adaptive Biotechnologies Corp. (NASDAQ:ADPT)
and  Microsoft Corp. (NASDAQ:MSFT), T-Detect launched on Tuesday as a laboratory developed test (LDT) to detect recent or prior COVID-19 infection. The test is also under FDA review for emergency use authorization (EUA) as an in vitro diagnostic (IVD). ...